Protalix BioTherapeutics, Inc.

AMEX:PLX

Biotechnology

Healthcare
$3.02 +4.21%

+$0.09 today

Market cap
$254.64M
Beta
0.01
P/E (TTM)
11.0
EPS (TTM)
$0.19
52W Low $1.32High $3.19

Volume 0.96M

Average 0.81M

Income Statement

Follow revenue through to earnings.

Revenue

$52.74M

FY 2025 · Annual

-1.2% YoY

Operating Income

-$5.50M

FY 2025 · Annual

Net Income

-$6.60M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue38.35M47.64M65.49M53.4M52.74M
Cost of Revenue16.35M19.59M22.98M24.32M27.51M
Gross Profit22M28.05M42.51M29.08M25.24M
Gross Margin57.4%58.9%64.9%54.5%47.8%
Research & Development29.73M29.35M17.09M12.97M19.05M
Selling, General & Admin12.73M11.71M14.96M12.19M11.68M
Operating Expenses42.46M41.06M32.05M25.16M30.74M
Depreciation & Amortization1.12M1.09M1.19M1.3M1.47M
EBITDA(18.94M)(10.78M)12.94M6.52M(2.95M)
EBITDA Margin-49.4%-22.6%19.8%12.2%-5.6%
Operating Income(20.46M)(13.01M)10.46M3.92M(5.5M)
Operating Margin-53.4%-27.3%16.0%7.3%-10.4%
Interest Income401K1.15M1.29M1.3M1.08M
Interest Expense7.52M2.53M3.18M1.06M1.19M
Other Income / Expenses(7.12M)(1.38M)(1.89M)237K(108K)
Income Before Tax(27.58M)(14.4M)8.57M4.15M(5.61M)
Pre-Tax Margin-71.9%-30.2%13.1%7.8%-10.6%
Income Tax Expense0530K254K1.22M996K
Net Income(27.58M)(14.93M)8.31M2.93M(6.6M)
Net Margin-71.9%-31.3%12.7%5.5%-12.5%
EPS (Basic)(0.62)(0.31)0.120.04(0.08)
EPS (Diluted)(0.62)(0.31)0.100.04(0.08)
Weighted Avg Shares44.14M48.47M67.51M72.53M78.55M
Weighted Avg Shares (Diluted)44.14M48.47M82.42M81.06M78.55M

PLX Earnings Waterfall · TTM

AMEX:PLX · Revenue to Net Income

Key Ratios

EPS$0.18
Gross Margin63.3%
Net Margin2.0%
P/E Ratio48.0
P/S Ratio9.5

Analysis

$76.4M of revenue converted into $15.3M of net income for the selected period. Gross margin is 63.3% and net margin is 2.0%, showing how much revenue survives after costs and taxes. EPS is $0.18, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 10, 2026
8-KCurrent reportNov 10, 2026
SC 13GSC 13G filingOct 15, 2026
4Statement of changes in beneficial ownershipSep 9, 2026
4Statement of changes in beneficial ownershipSep 4, 2026

How much revenue does PLX generate?

Protalix BioTherapeutics, Inc. (PLX) reported $52.74M of revenue in fiscal 2025.

Is PLX profitable?

Protalix BioTherapeutics, Inc. (PLX) reported -$6.60M of net income, with a net margin of -12.5%.